Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40microg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG in Plasma Donors Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection
Latest Information Update: 27 Feb 2018
Price :
$35 *
At a glance
- Drugs Botulism vaccine (Primary)
- Indications Botulism
- Focus Pharmacodynamics
- 20 Feb 2018 Primary endpoint (Four-Fold Increase in Neutralizing Antibody Concentration (NAC)) has been met, according to the results published in the Vaccine
- 20 Feb 2018 Results published in the Vaccine
- 28 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.